- Bend Bioscience has opened four new manufacturing suites, completing its 14,000-square-foot process science facility in Bend, Oregon.
- The expansion supports cGMP early-phase development of oral and inhalation dosage forms, including spray drying and encapsulation.
Bend Bioscience has announced the opening of four additional process development and manufacturing suites at its Bend, Oregon facility, bringing the site’s total to seven cGMP suites dedicated to early-phase pharmaceutical manufacturing.
The new 14,000-square-foot expansion enhances capabilities for oral and inhalation drug development. It includes facilities for granulation, encapsulation, compression, and coating, as well as a low humidity suite tailored for dry powder inhalation and moisture-sensitive materials. The site now hosts a second pilot-scale spray dryer with 300kg/hr gas flow capacity and equipment for secondary drying and tablet production.
This infrastructure investment is intended to address rising demand for particle engineering and spray drying solutions to support improved absorption and pulmonary delivery. “This latest extension provides additional capacity and capabilities to meet growing demand from clients,” said Owen Murray, CEO of Bend Bioscience. “We are proud to showcase both our state-of-the-art facility and equipment as well as our high science and high service culture.”
The announcement follows plans to install a commercial PSD-4 spray dryer at the company’s Gainesville, Georgia site, further strengthening its role as a CDMO partner in formulation and process development.
Stay ahead of trends and best practices
